Current Report Filing (8-k)
25 Avril 2023 - 2:01PM
Edgar (US Regulatory)
0001832511
false
0001832511
2023-04-25
2023-04-25
0001832511
us-gaap:CommonClassAMember
2023-04-25
2023-04-25
0001832511
us-gaap:WarrantMember
2023-04-25
2023-04-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
April 25, 2023
P3 Health Partners Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40033 |
|
85-2992794 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
|
2370 Corporate Circle, Suite 300 |
|
|
Henderson, NV |
89074 |
|
(Address of principal executive offices) |
(Zip Code) |
(702) 910-3950
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading |
|
Name of each exchange |
|
|
Symbol(s) |
|
on which registered |
Class A Common Stock, par value $0.0001 per share |
|
PIII |
|
The Nasdaq Stock Market LLC |
Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50. |
|
PIIIW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
The
Board of Directors of P3 Health Partners Inc. (the “Company”) has established July 24, 2023 as the date of the
Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). The 2023 Annual Meeting will be held virtually
by means of remote communication. The details of the virtual annual meeting, including how stockholders can log into the virtual meeting,
vote and submit questions, will be disclosed in the Company’s definitive proxy statement for the 2023 Annual Meeting to be filed
with the Securities and Exchange Commission.
Any stockholder seeking to bring business before the 2023 Annual Meeting
or to nominate a director must provide timely notice, as set forth in the Company’s Bylaws (the “Bylaws”). Specifically,
written notice of any proposed business or nomination must be received at the Company’s principal executive offices no later than
May 5, 2023 (which is the tenth day following this public announcement of the date of the 2023 Annual Meeting). Any notice of proposed
business or nomination must comply with the specific requirements set forth in the Bylaws. In addition to satisfying the requirements
under the Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees
other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).
Stockholders who intend to have a proposal considered for inclusion
in the Company’s 2023 proxy materials for presentation at its 2023 Annual Meeting pursuant to Rule 14a-8 under the Exchange
Act must submit the proposal in writing to the Company’s Corporate Secretary at its principal executive offices by May 5, 2023.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
P3 Health Partners Inc. |
|
|
|
|
Date: |
April 25, 2023 |
By: |
/s/ Jessica Puathasnanon |
|
|
|
Jessica Puathasnanon |
|
|
|
Chief Legal Officer |
Foresight Acquisition (NASDAQ:FORE)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
Foresight Acquisition (NASDAQ:FORE)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
Real-Time news about Foresight Acquisition Corp (NASDAQ): 0 recent articles
Plus d'articles sur P3 Health Partners Inc.